Home
/
Evofem Biosciences, Inc.
/
Financials
/
Quarterly
Evofem Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Evofem Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Oct 31, 2023
$100.00M
Nov 14, 2023
Q3
2022
Sep 30, 2022
$6.37M
Jan 6, 2023
Q2
2022
Jun 30, 2022
$6.03M
Aug 12, 2022
Q1
2022
Mar 31, 2022
$4.25M
May 10, 2022
Q3
2022
Sep 30, 2021
$1.71M
Jan 6, 2023
Q2
2022
Jun 30, 2021
$1.86M
Aug 12, 2022
Q1
2022
Mar 31, 2021
$1.11M
May 10, 2022
Q3
2021
Sep 30, 2020
$278.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$0
Aug 11, 2021
Q1
2021
Mar 31, 2020
$0
May 6, 2021
Q3
2020
Sep 30, 2019
$0
Nov 9, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$4.95M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$4.83M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$845.0K
May 15, 2025
Q3
2025
Sep 30, 2024
$4.50M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$4.16M
Aug 14, 2025
Q1
2025
Mar 31, 2024
$3.60M
May 15, 2025
Q3
2024
Sep 30, 2023
$5.11M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$2.46M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$5.81M
May 15, 2024
Q3
2023
Sep 30, 2022
$6.37M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$6.03M
Aug 14, 2023
Q1
2023
Mar 31, 2022
$4.25M
Jun 16, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.57M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($1.78M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($1.78M)
Nov 13, 2025
Q3
2025
Mar 31, 2025
$956.0K
Nov 13, 2025
Q1
2025
Mar 31, 2025
$956.0K
May 15, 2025
Q2
2025
Mar 31, 2025
$956.0K
Aug 14, 2025
Q3
2025
Sep 30, 2024
($2.37M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
$1.35M
Aug 14, 2025
Q3
2025
Jun 30, 2024
$1.35M
Nov 13, 2025
Q3
2025
Mar 31, 2024
($4.81M)
Nov 13, 2025
Q2
2025
Mar 31, 2024
($4.81M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($4.81M)
May 15, 2025
Q3
2024
Sep 30, 2023
$66.01M
Nov 14, 2024
Q3
2024
Jun 30, 2023
($8.56M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($8.56M)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($2.35M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($2.35M)
May 15, 2024
Q2
2024
Mar 31, 2023
($2.35M)
Aug 14, 2024
Q3
2023
Sep 30, 2022
$89.51M
Nov 14, 2023
Q3
2023
Jun 30, 2022
($125.98M)
Nov 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$951.0K
Nov 13, 2025
Q2
2025
Jun 30, 2025
($1.25M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
$327.0K
May 15, 2025
Q3
2025
Sep 30, 2024
($2.44M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($1.39M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.84M)
May 15, 2025
Q3
2024
Sep 30, 2023
($3.55M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($7.34M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($3.58M)
May 15, 2024
Q3
2023
Sep 30, 2022
($18.72M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($24.42M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($28.93M)
Jun 16, 2023
Q3
2022
Sep 30, 2021
($43.37M)
Jan 6, 2023
Q2
2022
Jun 30, 2021
($41.14M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($44.87M)
May 10, 2022
Q3
2021
Sep 30, 2020
($26.16M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($22.37M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
($19.24M)
May 6, 2021
Q3
2020
Sep 30, 2019
($14.30M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($11.94M)
Aug 4, 2020